Publications by authors named "Allen King"

Claim this Profile
E
Excessive Basal Insulin Dosage When Following the Accepted Titration Method.
Allen B King

Endocr Pract· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on continuous subcutaneous insulin infusion or once-nightly basal insulin.
Allen B King

Diabetes Obes Metab· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
Allen B King, Athena Philis-Tsimikas, Eric S Kilpatrick, Irene H Langbakke, Kamilla Begtrup

Diabetes Technol Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.
Allen B King, Akio Kuroda, Munehide Matsuhisa, Todd Hobbs

Curr Diab Rep· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isotherm ranking and selection using thirteen literature datasets involving hydrophobic organic compounds.
L Shawn Matott, Zhengzheng Jiang, Alan J Rabideau, Richelle M Allen-King

J Contam Hydrol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal Hyporheic Zone Response to Water Table Fluctuations.
Jonathan M Malzone, Sierra K Anseeuw, Christopher S Lowry, Richelle Allen-King

Ground Water· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Daniel Einhorn, Yehuda Handelsman, Bruce W Bode, Lars A Endahl, Henriette Mersebach, Allen B King

Endocr Pract· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misled by the Morning "Fasting" Plasma Glucose.
Allen B King

J Diabetes Sci Technol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omitting late-night eating may cause hypoglycemia in "well controlled" basal insulin-treated type 2 diabetes.
Allen B King, Dawn Clark

Endocr Pract· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
Richard Simpson, Allen King

Expert Rev Clin Pharmacol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and gene expression of porcine cloned embryos derived from bone marrow stem cells with overexpressing Oct4 and Sox2.
Jeong-Hyeon Lee, Won-Jae Lee, Ryoung-Hoon Jeon, Yeon-Mi Lee, Si-Jung Jang, W Allen King

Cell Reprogram· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneous carbonaceous matter in sedimentary rock lithocomponents causes significant trichloroethylene (TCE) sorption in a low organic carbon content aquifer/aquitard system.
Sungwook Choung, Lisa R Zimmerman, Richelle M Allen-King, Bertrand Ligouis, Stanley Feenstra

J Contam Hydrol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualizing insulin therapy in the management of type 2 diabetes.
Etie Moghissi, Allen B King

Am J Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessment of insulin dosing guidelines in continuous subcutaneous insulin infusion treated type 1 diabetes.
Allen Bennett King

Curr Diab Rep· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When is enough, enough? The correlation between once-daily basal insulin doses to the fasting plasma glucose in type 2 diabetes.
Allen B King

Endocr Pract· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating advances in insulin into clinical practice: Advances In insulin formulations.
Allen King

J Fam Pract· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
Allen B King, Eduard Montanya, Richard E Pratley, Lawrence Blonde, Claus Bo Svendsen

Endocr Pract· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Titrating beyond glycemic goal: "post-glycemic target phenomenon".
Allen B King, Dawn Clark, Gary S Wolfe

J Diabetes Sci Technol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight versus pre-insulin-treatment assessment of insulin sensitivity to determine the starting basal insulin dose: a faster way to get to goal?
Allen B King, Dawn Clark, Gary S Wolfe

J Diabetes Sci Technol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.
Allen B King, Dawn Clark, Gary S Wolfe

Endocr Pract· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Irl B Hirsch, Bruce Bode, Jean-Pierre Courreges, Patrik Dykiel, Edward Franek, Allen King

Diabetes Care· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The number of basal rates required to achieve near-normal basal glucose control in pump-treated type 2 diabetes.
Allen B King, Dawn Clark, Gary S Wolfe

Diabetes Technol Ther· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution of carbonaceous matter in lithofacies: impacts on HOC sorption nonlinearity.
Indra Kalinovich, Richelle M Allen-King, Kathryn Thomas

J Contam Hydrol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in insulin therapy: a review of insulin degludec.
Allen King

J Fam Pract· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci

Lancet· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis